LEXXNasdaqPharmaceutical PreparationsFiscal year ends August 31
Lexaria Bioscience Corp.
Financials through Q3 FY2026, quarter ended May 31, 2026Last filing: 10-Q on Jul 13, 2026
$2.60−0.26 (-9.09%)
Close on Oct 19, 2026
- Market cap
- $64.50M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$9.89 (−79.18%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Split
Lexaria Bioscience Corp. saw revenue fall 68.5% to $194.00K over the twelve months to May 31, 2026. Free cash flow was -$7.47M.
Revenue
$194.00K
-68.5% vs. a year earlier
Operating income
-$7.71M
TTM Q3 2026
Free cash flow
-$7.47M
TTM Q3 2026
EPS, diluted
-$0.35
TTM Q3 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at May 31, 2026
Valuation
- Market cap
- $64.50M
- P/E ratio
- –
- Price to sales
- 332.45
- Price to book
- 13.61
- Dividend yield
- –
- Free cash flow yield
- -11.58%
Fundamentals
- Revenue
- $194.00K
- Net income
- -$7.73M
- EPS, diluted
- -$0.35
- Free cash flow
- -$7.47M
- Book value per share
- $0.19
- Diluted shares
- 25M
Fifteen years at a glance
Fiscal years 2010 to 2025 and trailing twelve months, USD
Revenue
$194.00K-68.5% YoY
Gross profit
$194.00K-68.4% YoY
Operating income
-$7.71M
Net income
-$7.73M
EPS, diluted
-$0.35
Free cash flow
-$7.47M
Reported periodTrailing twelve months